Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma
NCT06485739
·
clinicaltrials.gov ↗
PHASE4
Phase
NOT_YET_RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Neuroendocrine Tumors
Interventions
DRUG:
Irinotecan liposomes combined with cisplatin/carboplatin
Sponsor
First Affiliated Hospital Xi'an Jiaotong University